Boston Children’s Hospital and ElevateBio Announce Five-Year Cell and Gene Therapy Collaboration
Boston Childrens Hospital, which has the largest National Institutes of Health-funded pediatric research enterprise in the United States, and ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that they have entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Childrens Hospital with an introduction to Boston Childrens translational research capabilities.
- Boston Childrens Hospital, which has the largest National Institutes of Health-funded pediatric research enterprise in the United States, and ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that they have entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Childrens Hospital with an introduction to Boston Childrens translational research capabilities.
- The agreement enables Boston Childrens and ElevateBio to form multiple cell and gene therapy companies together; provides Boston Childrens researchers access to ElevateBios core-enabling technologies, manufacturing, and leading expertise to advance their programs; and will guarantee Boston Childrens researchers dedicated viral-vector manufacturing space at ElevateBio BaseCamp, ElevateBios centralized world-class research and development manufacturing center.
- At Boston Childrens Hospital, we are proud of the foundation weve established as a leading innovator in cell and gene therapy, so collaborating with ElevateBio a company so well-positioned to change the face of cell and gene therapy forever is a natural fit into our overall vision, said David Williams, M.D., formerly Senior Vice President for Research and Chief Scientific Officer, currently Chief of Hematology / Oncology, Boston Children's Hospital.
- Boston Childrens Hospital has a strong history of innovation in the cell and gene therapy sector through ground-breaking science and spinning out companies to deliver medicines to patients.